Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma
Objectives: The purpose of the study was to assess the relationship between selective serotonin reuptake inhibitors use and hepatocellular carcinoma in Taiwan.Methods: Using the database of the Taiwan National Health Insurance Program, we conducted a case-control study to identify 4901 subjects aged...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00861/full |
| _version_ | 1819087992959008768 |
|---|---|
| author | Shih-Wei Lai Shih-Wei Lai Kuan-Fu Liao Kuan-Fu Liao Cheng-Li Lin Cheng-Li Lin Hsien-Feng Lin Hsien-Feng Lin |
| author_facet | Shih-Wei Lai Shih-Wei Lai Kuan-Fu Liao Kuan-Fu Liao Cheng-Li Lin Cheng-Li Lin Hsien-Feng Lin Hsien-Feng Lin |
| author_sort | Shih-Wei Lai |
| collection | DOAJ |
| description | Objectives: The purpose of the study was to assess the relationship between selective serotonin reuptake inhibitors use and hepatocellular carcinoma in Taiwan.Methods: Using the database of the Taiwan National Health Insurance Program, we conducted a case-control study to identify 4901 subjects aged 20 years and more with newly diagnosed hepatocellular carcinoma in 2000–2013 as the cases. We randomly selected 19604 subjects aged 20 years and more without hepatocellular carcinoma as the controls. Both cases and controls were matched with sex and age. Ever use of selective serotonin reuptake inhibitors was defined as a subject who had at least a prescription for selective serotonin reuptake inhibitors before index date. Never use was defined as a subject who never had a prescription for selective serotonin reuptake inhibitors before index date. The odds ratio (OR) and 95% confidence interval (CI) for hepatocellular carcinoma associated with selective serotonin reuptake inhibitors use was estimated by the multivariable logistic regression model.Results: Among subjects with any one of the comorbid conditions associated with hepatocellular carcinoma, the adjusted OR of hepatocellular carcinoma was 0.89 (95% CI 0.75, 1.06) for subjects with ever use of selective serotonin reuptake inhibitors, comparing with never use.Conclusion: The findings indicate that among subjects with any one of the comorbid conditions associated with hepatocellular carcinoma, no significant association can be detected between selective serotonin reuptake inhibitors use and hepatocellular carcinoma. |
| first_indexed | 2024-12-21T21:44:58Z |
| format | Article |
| id | doaj.art-66966de849e7484dbb2a6a9ceb52b85a |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-21T21:44:58Z |
| publishDate | 2017-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-66966de849e7484dbb2a6a9ceb52b85a2022-12-21T18:49:15ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122017-11-01810.3389/fphar.2017.00861318143Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular CarcinomaShih-Wei Lai0Shih-Wei Lai1Kuan-Fu Liao2Kuan-Fu Liao3Cheng-Li Lin4Cheng-Li Lin5Hsien-Feng Lin6Hsien-Feng Lin7Department of Medicine, China Medical University, Taichung, TaiwanDepartment of Family Medicine, China Medical University Hospital, Taichung, TaiwanDepartment of Medicine, Tzu Chi University, Hualien, TaiwanDepartment of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, TaiwanDepartment of Medicine, China Medical University, Taichung, TaiwanManagement Office for Health Data, China Medical University Hospital, Taichung, TaiwanDepartment of Family Medicine, China Medical University Hospital, Taichung, TaiwanDepartment of Chinese Medicine, China Medical University, Taichung, TaiwanObjectives: The purpose of the study was to assess the relationship between selective serotonin reuptake inhibitors use and hepatocellular carcinoma in Taiwan.Methods: Using the database of the Taiwan National Health Insurance Program, we conducted a case-control study to identify 4901 subjects aged 20 years and more with newly diagnosed hepatocellular carcinoma in 2000–2013 as the cases. We randomly selected 19604 subjects aged 20 years and more without hepatocellular carcinoma as the controls. Both cases and controls were matched with sex and age. Ever use of selective serotonin reuptake inhibitors was defined as a subject who had at least a prescription for selective serotonin reuptake inhibitors before index date. Never use was defined as a subject who never had a prescription for selective serotonin reuptake inhibitors before index date. The odds ratio (OR) and 95% confidence interval (CI) for hepatocellular carcinoma associated with selective serotonin reuptake inhibitors use was estimated by the multivariable logistic regression model.Results: Among subjects with any one of the comorbid conditions associated with hepatocellular carcinoma, the adjusted OR of hepatocellular carcinoma was 0.89 (95% CI 0.75, 1.06) for subjects with ever use of selective serotonin reuptake inhibitors, comparing with never use.Conclusion: The findings indicate that among subjects with any one of the comorbid conditions associated with hepatocellular carcinoma, no significant association can be detected between selective serotonin reuptake inhibitors use and hepatocellular carcinoma.http://journal.frontiersin.org/article/10.3389/fphar.2017.00861/fullhepatocellular carcinomaselective serotonin reuptake inhibitorsTaiwanNational Health Insurance Programcase-control study |
| spellingShingle | Shih-Wei Lai Shih-Wei Lai Kuan-Fu Liao Kuan-Fu Liao Cheng-Li Lin Cheng-Li Lin Hsien-Feng Lin Hsien-Feng Lin Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma Frontiers in Pharmacology hepatocellular carcinoma selective serotonin reuptake inhibitors Taiwan National Health Insurance Program case-control study |
| title | Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma |
| title_full | Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma |
| title_fullStr | Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma |
| title_full_unstemmed | Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma |
| title_short | Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma |
| title_sort | case control study examining the association between selective serotonin reuptake inhibitors use and hepatocellular carcinoma |
| topic | hepatocellular carcinoma selective serotonin reuptake inhibitors Taiwan National Health Insurance Program case-control study |
| url | http://journal.frontiersin.org/article/10.3389/fphar.2017.00861/full |
| work_keys_str_mv | AT shihweilai casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma AT shihweilai casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma AT kuanfuliao casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma AT kuanfuliao casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma AT chenglilin casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma AT chenglilin casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma AT hsienfenglin casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma AT hsienfenglin casecontrolstudyexaminingtheassociationbetweenselectiveserotoninreuptakeinhibitorsuseandhepatocellularcarcinoma |